Loading clinical trials...
Loading clinical trials...
The goal of this study is to demonstrate the feasibility of mapping tau pathology in subjects with Primary Progressive Aphasia, using PET protocol with F-AV-1451 (trade name AV-1451) and to systematically document the extent and location of tau pathology in PPA patients in vivo using the same techniques.
Age
20 - 100 years
Sex
ALL
Healthy Volunteers
No
University of Chicago - American School Building
Chicago, Illinois, United States
Start Date
February 1, 2016
Primary Completion Date
February 28, 2025
Completion Date
February 28, 2025
Last Updated
April 6, 2025
70
ESTIMATED participants
18F-AV-1451
DRUG
PET
DEVICE
Lead Sponsor
University of Chicago
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions